Neferine

CAS No. 2292-16-2

Neferine( (-)-Neferine )

Catalog No. M18271 CAS No. 2292-16-2

Neferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 39 In Stock
10MG 65 In Stock
25MG 125 In Stock
50MG 210 In Stock
100MG 311 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Neferine
  • Note
    Research use only, not for human use.
  • Brief Description
    Neferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity.
  • Description
    Neferine has anti-tumor activities , Metabolic activation mediated by CYP3A4 and GSH depletion enhanced Neferine-induced cytotoxicity. Neferine can be helpful to increase the efficacy of DOX and to achieve anticancer synergism by curbing the toxicity. Neferine inhibited high glucose-induced endothelial apoptosis via blocking ROS/Akt/NF-κB pathway, which provides the evidence for using Neferine to treat diabetic vasculopathy. Neferine induced apoptosis in a dose-dependent manner with the hypergeneration of reactive oxygen species, activation of MAPKs, lipid peroxidation, depletion of cellular antioxidant pool, loss of mitochondrial membrane potential, and intracellular calcium accumulation.
  • In Vitro
    Neferine down regulates hypoxia induced NF-κB p65 nuclear translocation and COX-2 expressions. Neferine reduces high-glucose-induced collagen production and inhibits TGF-β1-Smad, ERK and p38 MAPK signaling activation in cardiac fibroblasts. Cardiac fibroblasts (CFs) are cultured in HG medium with varying concentrations of Neferine (1, 2, or 5 μM). CCK-8 assays are carried out at different time points (24, 48, and 72 h). Compared with normal glucose (NG) and osmotic control (OC) treatments, High glucose (30 mM) treatment significantly increases the proliferation of CFs in a time-dependent manner (P<0.05). High glucose (HG)-induced CF proliferation is markedly attenuated by Neferine treatment at either 2 or 5 μM compared with vehicle treatment. However, 1 μM Neferine does not inhibit HG-induced proliferation of CFs. Therefore, 2 and 5 μM Neferine are used in the remaining experiments.
  • In Vivo
    Neferine treatment at both low-dose (60 mg/kg/day by gavage) and high-dose (120 mg/kg/day by gavage) reduces the increment of collagen I, III and TGF-β1 protein expression induced by hyperglycemia.
  • Synonyms
    (-)-Neferine
  • Pathway
    Neuroscience
  • Target
    GluR
  • Recptor
    Others
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    2292-16-2
  • Formula Weight
    624.77
  • Molecular Formula
    C38H44N2O6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO : 62 mg/mL 99.24 mM;
  • SMILES
    CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)OC)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • OSI-420

    OSI-420 (Desmethyl Erlotinib, CP-473420) is an active metabolite of erlotinib which is an orally active EGFR tyrosin kinase inhibitor with IC50 of 2 and 20 nM for human EGFR and EGFR autophosphorylation in tumor cells.

  • GYKI 52466 dihydroch...

    GYKI 52466 dihydrochloride (GYKI 52466 2HCl) is a highly potent, orally active and selective AMPA/Kainate receptor antagonist with good blood-brain permeability and anticonvulsant activity that can be used to study neurological diseases such as Parkinson's and epilepsy.

  • Chelidamic acid

    Chelidamic acid is a heterocyclic organic acid with a pyran skeleton. Chelidamic acid is inhibitors of glutamate decarboxylase with a Ki of 33 μM.